Japanese
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

anticonvulsant/obesity

リンクがクリップボードに保存されます
ページ 1 から 103 結果

Bodyweight gain and anticonvulsants: a comparative review.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Bodyweight gain is a common and frequent undesirable effect associated with the use of anticonvulsant drugs. This has been observed for many years with valproic acid (sodium valproate) and carbamazepine, and also, more recently, with some of the newer anticonvulsants such as vigabatrin and

Targets for medical therapy in obesity.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Obesity has more than doubled since 1980 all over the world, and in the European perspective it does not seem to be better. Obesity-related diseases like diabetes, hypertension, coronary heart disease, stroke and hyperlipidemia are the main cause of mortality and morbidity in developed countries.

Three children with a syndrome of obesity and overgrowth, atypical psychosis, and seizures: a problem in neuropsychopharmacology.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Three children presented with a complex syndrome of atypical psychotic and extremely immature behavior, obesity and overgrowth, borderline retardation, and seizures (prominent in two). Weight overgrowth exceeded height overgrowth and was stratospheric (up to 8 SD above mean). Obesity seemed related

Clinical evaluation of anti-obesity drugs.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with

Obesity: new perspectives and pharmacotherapies.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
There is a widespread epidemic of obesity in the United States, which has been associated with an increased risk of diabetes mellitus, cancer, and cardiovascular diseases. Although lifestyle modifications and long-term dietary vigilance remain cornerstones of weight reduction treatment, the

Increased response of plasma allopregnanolone to corticotropin-releasing hormone in obese patients.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Allopregnanolone is a neuroactive steroid present in the brain, but also measurable in systemic circulation. It exhibits anxiolytic and anticonvulsant effects and is able to produce hyperphagia. Since eating behavior disturbances and increased peripheral basal sympathetic activity have been reported

Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans. The present study was designed to evaluate the weight-controlling properties of topiramate in dietary obese female rats in comparison with sibutramine. METHODS Fifty rats were assigned as

The role of prescription medications in the association of self-reported sleep duration and obesity in U.S. adults, 2007-2012.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Previous research has not investigated the role of prescription medication in sleep-obesity associations despite the fact that 56% of U.S. adults take at least one prescription medication. Data from n = 16,622 adults in the National Health and Nutrition Examination Survey (2007-2012) were used to

Obesity, polycystic ovarian syndrome and thyroid dysfunction in women with epilepsy.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Women with epilepsy (WWE) have an increased risk for several endocrine disorders. Obesity and Polycystic Ovarian Syndrome (PCOS) are common side-effects of anticonvulsant drugs. OBJECTIVE To study the prevalence of Obesity, PCOS, Thyroid dysfunction in WWE on monotherapy with

Evaluation of a rat model of valproate-induced obesity.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
Long-term treatment with the anticonvulsant valproate (VPA) leads to well-documented weight gain and obesity in humans. In an attempt to develop an animal model of this condition, adult rats were given VPA 20 g/kg (high-dose) or 2 g/kg (low-dose) in their daily feeding or orally 120 mg/kg body

Febrile convulsions, ataxia, developmental delay, and obesity: a new syndrome?

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
We describe the association of recurrent complicated febrile convulsions, developmental delay, ataxia, and obesity in three unrelated girls. The three girls, aged 3 to 4 years, were all born to healthy, nonconsanguineous parents and have normal siblings. Their birth weight was appropriate for

Do obese depressed patients respond to topiramate? A retrospective chart review.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND Topiramate, a novel anticonvulsant, has shown promise in preliminary open trials in bipolar disorder, but there are no studies in primary depression. Topiramate's tendency to cause weight loss could be advantageous for many patients with mood disorders. METHODS A chart review was

Add-on topiramate reduces weight in overweight patients with affective disorders: a clinical case series.

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
BACKGROUND The weight-gain caused by many psychotropic drugs is a major cause for poor compliance with such medications and could also increase cardio-vascular morbidity among psychiatric patients. Recent reports have shown that the anticonvulsant topiramate causes weight loss in various patient
BACKGROUND Pain after laparoscopic gastric bypass surgery (LGBP) is a major problem. Gabapentin is an anticonvulsant drug that can be effective in postoperative pain control. OBJECTIVE This study examined the effect of preoperative administration of gabapentin on reducing pain after LGBP in patients

[Prevalence of psychoactive drug consumption in an obese population].

登録ユーザーのみが記事を翻訳できます
ログインサインアップ
OBJECTIVE To establish the prevalence of psychoactive drug consumption in an obese population. METHODS We collected data from the clinical records of obese patients attending the Endocrinology and Nutrition Department and Psychiatry Department of Hospital del Mar between June 2005 and May 2006
Facebookページに参加する

科学に裏打ちされた最も完全な薬草データベース

  • 55の言語で動作します
  • 科学に裏打ちされたハーブ療法
  • 画像によるハーブの認識
  • インタラクティブGPSマップ-場所にハーブをタグ付け(近日公開)
  • 検索に関連する科学出版物を読む
  • それらの効果によって薬草を検索する
  • あなたの興味を整理し、ニュース研究、臨床試験、特許について最新情報を入手してください

症状や病気を入力し、役立つ可能性のあるハーブについて読み、ハーブを入力して、それが使用されている病気や症状を確認します。
*すべての情報は公開された科学的研究に基づいています

Google Play badgeApp Store badge